Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions-Reference-Cited by-同舟云学术

Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions

Published:2011-02-24 Issue:3 Volume:32 Page:175-184
ISSN:0142-2782
Container-title:Biopharmaceutics & Drug Disposition
language:en
Short-container-title:Biopharm. Drug Dispos.

Author:

Choi Min-Koo,Jin Qing-Ri,Choi Yeong-Lim,Ahn Sung-Hoon,Bae Myung-Ae,Song Im-Sook

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/bdd.749/fullpdf

Reference33 articles.

1. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study;Zhao;J Clin Pharmacol,2009

2. Transporter-mediated drug interactions: clinical implications and in vitro assessment;Lin;Expert Opin Drug Metab Toxicol,2007

3. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus;Khaliq;Clin Pharmacol Ther,2000

4. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression;Gibbs;Drug Metab Dispos,1999

5. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes;Choo;Drug Metab Dispos,2000

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survey of Pharmaceutical Industry’s Best Practices around In Vitro Transporter Assessment and Implications for Drug Development: Considerations from the International Consortium for Innovation and Quality for Pharmaceutical Development Transporter Working Group;Drug Metabolism and Disposition;2024-05-02

2. Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib;Clinical Pharmacology in Drug Development;2024-02-29

3. Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases;Journal of Medicinal Chemistry;2024-02-13

4. Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug–Drug Interactions in Rats;Pharmaceutics;2023-03-10

5. Pharmacokinetic Drug-drug Interaction of Antibiotics Used in Sepsis Care in China;Current Drug Metabolism;2021-03-22